In a small safety trial based on preclinical work by a Stanford researcher, participants receiving blood plasma infusions from young donors showed some evidence of improvement.

Stanford University School of Medicine investigators have reported success in an early-phase clinical trial examining the safety, tolerability and feasibility of administering infusions of blood plasma from young donors to participants with mild to moderate Alzheimer’s disease. There were also some signs suggesting improvements in participants’ conditions.

Results from the PLASMA trial, short for Plasma for Alzheimer’s Symptom Amelioration, were presented Nov. 4 at the 10th annual Clinical Trial on Alzheimer’s Disease conference in Boston by Sharon Sha, MD, a clinical associate professor of neurology and...

In a small safety trial based on preclinical work by a Stanford researcher, participants receiving blood plasma infusions from young donors showed some evidence of improvement.

Stanford University School of Medicine investigators have reported success in an early-phase clinical trial examining the safety, tolerability and feasibility of administering infusions of blood plasma from young donors to participants with mild to moderate Alzheimer’s disease. There were also some signs suggesting improvements in participants’ conditions.

Results from the PLASMA trial, short for Plasma for Alzheimer’s Symptom Amelioration, were presented Nov. 4 at the 10th annual Clinical Trial on Alzheimer’s Disease conference in Boston by Sharon Sha, MD, a clinical associate professor of neurology and neurological sciences at Stanford and the trial’s principal investigator.